Skip to content
Strategists tell Yahoo Finance the debates aren't the biggest concern among investors....
Michael Weisbach - Ohio State University Professor of Finance joins Yahoo Finance's On The Move panel to discuss what investors should look out for in Palantir's public debut....
Yahoo Finance's Adam Shaprio breaks down how Nikola and Disney are faring on Wednesday....
French investigators have called for a review of the design and maintenance of titanium alloy engine parts to ensure they guard against the risks of metal fatigue following an engine blowout on an Airbus A380 exactly three years ago. France's BEA agency made the recommendation in a final report into the accident in which an Air France jet carrying more than 500 passengers lost the front section of one of its four engines while flying over Greenland, before landing safely in Canada....
(Bloomberg) -- When Jan Skvarka joined biotechnology firm Trillium Therapeutics Inc. as chief executive officer, he made a big bet to reshape the company and went all-in on a cancer treatment platform. Now, he’s reaping the rewards.It was the gamble of a lifetime for the 53-year-old CEO, who decided to shutter the drug developer’s lead program on treating tumors directly and instead focus on cancer-fighting technology for patients with different blood cancers. Investors cheered, rewarding him with a 3,600% stock-surge since he joined the company a year ago.Trillium is the No. 1 stock on Canada’s S&P/TSX Composite Index this year, skyrocketing past tech behemoth Shopify Inc. by almost 10-fold. It’s U.S.-listed shares are the fourth best-performing company on the Nasdaq Composite Index.Despite its epic stock-market rally, every analyst covering the company rates it a buy, signaling that further gains are on the horizon for investors that missed out on Trillium’s initial...
Mark Cash, Morningstar equity analyst, joins Yahoo Finance’s The First Trade with Alexis Christoforous and Brian Sozzi to discuss Palantir’s debut on the New York Stock Exchange....
